Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BXRXNASDAQ:CLBSOTCMKTS:EMMANASDAQ:GRNV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBXRXBaudax Bio$0.02$0.02$0.01▼$3.47$1.14M1.57281,029 shs310,872 shsCLBSCaladrius Biosciences$6.37$0.38▼$1.24$26.05M0.91522,308 shs466,373 shsEMMAEmmaus Life Sciences$0.01-0.7%$0.01$0.00▼$0.10$890K7.5524,313 shs500 shsGRNVGreenVision Acquisition$10.89$7.70▼$25.30$37K0.07105,738 shs1.54 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBXRXBaudax Bio0.00%0.00%0.00%0.00%0.00%CLBSCaladrius Biosciences0.00%0.00%0.00%0.00%0.00%EMMAEmmaus Life Sciences-0.72%-8.00%-12.66%-18.82%-84.89%GRNVGreenVision Acquisition0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBXRXBaudax BioN/AN/AN/AN/AN/AN/AN/AN/ACLBSCaladrius BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AEMMAEmmaus Life Sciences0.3524 of 5 stars0.02.00.00.01.91.70.0GRNVGreenVision AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBXRXBaudax Bio 0.00N/AN/AN/ACLBSCaladrius Biosciences 0.00N/AN/AN/AEMMAEmmaus Life Sciences 0.00N/AN/AN/AGRNVGreenVision Acquisition 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBXRXBaudax Bio$1.27M0.90N/AN/A($14.93) per share0.00CLBSCaladrius BiosciencesN/AN/AN/AN/A$1.54 per shareN/AEMMAEmmaus Life Sciences$16.65M0.05N/AN/A($0.88) per share-0.02GRNVGreenVision AcquisitionN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBXRXBaudax Bio-$58.79M-$9.23N/AN/AN/AN/AN/A-175.11%N/ACLBSCaladrius Biosciences-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/AEMMAEmmaus Life Sciences-$6.45M-$0.11N/A∞N/A-26.79%N/A-17.85%N/AGRNVGreenVision Acquisition-$510KN/A0.00N/AN/AN/A-54.82%-2.65%N/ALatest BXRX, GRNV, EMMA, and CLBS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025EMMAEmmaus Life SciencesN/A-$0.04N/A-$0.04N/AN/A4/14/2025Q4 2024EMMAEmmaus Life SciencesN/A-$0.03N/A-$0.03N/A$3.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBXRXBaudax BioN/AN/AN/AN/AN/ACLBSCaladrius BiosciencesN/AN/AN/AN/AN/AEMMAEmmaus Life SciencesN/AN/AN/AN/AN/AGRNVGreenVision AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBXRXBaudax BioN/A0.070.07CLBSCaladrius BiosciencesN/A22.3322.33EMMAEmmaus Life SciencesN/A0.090.06GRNVGreenVision AcquisitionN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBXRXBaudax Bio9.05%CLBSCaladrius Biosciences15.57%EMMAEmmaus Life Sciences7.42%GRNVGreenVision AcquisitionN/AInsider OwnershipCompanyInsider OwnershipBXRXBaudax Bio0.10%CLBSCaladrius Biosciences2.20%EMMAEmmaus Life Sciences35.00%GRNVGreenVision Acquisition42.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBXRXBaudax Bio952.46 million52.41 millionNot OptionableCLBSCaladrius Biosciences2760.58 million59.25 millionOptionableEMMAEmmaus Life Sciences6063.87 million41.51 millionNot OptionableGRNVGreenVision AcquisitionN/A3.35 millionN/ANot OptionableBXRX, GRNV, EMMA, and CLBS HeadlinesRecent News About These CompaniesHelbiz IPO (HLBZ) StockAugust 20, 2021 | benzinga.comSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of GreenVision Acquisition Corp. (NasdaqAugust 17, 2021 | fintechzoom.comFScooter-Share Helbiz’s Friday 13th Debut Shows SPAC RefundsAugust 13, 2021 | finance.yahoo.comWhy GreenVision's Stock Is Skyrocketing TodayAugust 13, 2021 | msn.comHelbiz, Inc. and Greenvision Acquisition Corp. Announce Closing of Business Combination; Helbiz to Trade on Nasdaq Under Symbol "HLBZ"August 13, 2021 | finance.yahoo.comHelbiz Partners with Lightning eMotors to Deploy Electric Vehicles for Fleet ManagementJuly 30, 2021 | finance.yahoo.comMicro-Mobility Leader, Helbiz, Launches E-Scooters in Reggio Emilia, ItalyJuly 26, 2021 | finance.yahoo.comMedia Sentiment Over TimeBXRX, GRNV, EMMA, and CLBS Company DescriptionsBaudax Bio NASDAQ:BXRXBaudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.Caladrius Biosciences NASDAQ:CLBSCaladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Emmaus Life Sciences OTCMKTS:EMMA$0.01 0.00 (-0.72%) As of 07/3/2025 11:51 AM EasternEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.GreenVision Acquisition NASDAQ:GRNVAs of April 1, 2021, operates as a subsidiary of Helbiz, Inc.. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
